Beijing Proji Pharmaceutical Technology

Beijing Proji Pharmaceutical Technology is a clinical-stage biotechnology company based in Beijing, China, dedicated to the discovery of innovative small molecule therapeutics. The company specializes in targeting challenging protein-protein interactions (PPIs), which are traditionally considered difficult-to-drug, using its proprietary fragment-based and structure-based drug design platforms. Its lead program, PJ-001, is a highly potent and selective MCL-1 inhibitor that has advanced into Phase 1 clinical trials for hematologic malignancies. Proji's research engine focuses on high-value oncology targets where traditional screening methods have failed. The company is supported by leading venture capital investors and maintains a robust pipeline of early-stage discovery programs.